Identifying optimal candidates for liver resection or transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma

BACKGROUND: Recommended as the first-line treatment for advanced unresectable hepatocellular carcinoma (HCC), sorafenib has been shown to prolong median overall survival (OS) for patients. However, advanced HCC sees high heterogeneity across patient groups. Recently, a growing number of studies have...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Shoujie, Zhang, Xiangnan, Wang, Mengmeng, Tan, Kai, Dou, Weijia, Fan, Qingling, Li, Huichen, Du, Xilin, Liu, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290527/
https://www.ncbi.nlm.nih.gov/pubmed/32566613
http://dx.doi.org/10.21037/atm.2020.02.83

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290527/
https://www.ncbi.nlm.nih.gov/pubmed/32566613
http://dx.doi.org/10.21037/atm.2020.02.83

Ejemplares similares